ADCY7 Antibody is a polyclonal immunoglobulin produced in rabbits against a synthesized peptide derived from the human ADCY7 protein (amino acids 191–240) . It specifically recognizes ADCY7, a calcium-inhibitable enzyme belonging to the adenylyl cyclase class-4/guanylyl cyclase family, which regulates intracellular cAMP levels .
ADCY7 is critical for modulating innate and adaptive immunity. Studies using ADCY7-deficient mice revealed its role in:
The ADCY7 antibody facilitated the identification of reduced lymphocyte counts in chimeric mice, highlighting its importance in hematopoiesis .
Acute Myeloid Leukemia (AML): ADCY7 supports leukemia cell survival by suppressing apoptosis and maintaining c-Myc expression . Knockdown experiments using ADCY7-targeting tools reduced cell growth by 30–40% in AML lines .
Hepatocellular Carcinoma (HCC): ADCY7 promotes CD8+ T-cell infiltration via nuclear translocation and CCL5 transcription, enhancing antitumor immunity . Exosomal ADCY7 reshapes the tumor microenvironment, making it a potential therapeutic target .
Cervical Cancer: High ADCY7 expression correlates with poor prognosis and immune cell infiltration (e.g., macrophages, neutrophils) .
ADCY7 transcript levels are elevated in the amygdala of individuals with major depressive disorder (MDD) and serotonin transporter knockout mice .
The SNP rs1064448 in ADCY7 influences threat-related amygdala reactivity, linking it to emotional regulation .
ADCY7 modulates cAMP synthesis, which impacts:
The ADCY7 antibody (Catalog #A11384) is commercially available from Boster Bio . Validation includes:
Specificity confirmed via Western blot, IHC, and ELISA across human and mouse samples .
Compatibility with multiple experimental platforms, including fluorescence-based assays .
While ADCY7 antibodies have proven invaluable, challenges remain:
ADCY7 is an enzyme that catalyzes the formation of cyclic adenosine monophosphate (cAMP) in response to G protein-coupled receptor activation. It plays a crucial role in various signaling cascades, including those triggered by thrombin and sphingosine 1-phosphate. ADCY7 regulates cAMP synthesis synergistically with stimulatory Gα proteins (GNA13 and Gβγ complexes), influencing pathways activated by agonists such as thrombin, sphingosine 1-phosphate, dopamine, and the C5 alpha chain. During inflammation, ADCY7 mediates zymosan-induced cAMP increases, activating protein kinase A and modulating innate immune responses via heterotrimeric G(12/13) proteins. Furthermore, ADCY7 regulates inflammation during bacterial infection by responding to serum factors like lysophosphatidic acid (LPA), influencing LPS-induced TNF-alpha production. Importantly, it is also essential for optimal B and T cell function in adaptive immunity by regulating cAMP synthesis in these cell types.
The functional significance of ADCY7 is underscored by numerous studies: